Pacific Biosciences is trading 5.14% lower at $2.31 after its November 4 earnings update narrowed 2026 revenue guidance. - Q3 revenue was $40.6 million; 2026 guidance is now $155 million–$160 million, versus $155 million–$165 million. - CFO Jim Gibson stepped down, and CEO Mark Van Oene is serving as interim CFO. - Major U.S. indexes were higher on November 6, so a broad-market decline does not explain the move.